Related Experiment Video
Updated: Sep 1, 2025

Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx
Published on: May 2, 2025
Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases
1Hebei Key Laboratory for Organ Fibrosis Research, School of Public Health, North China University of Science and Technology, Tangshan 063210, China.
Abstract:
As a critical molecule in the onset and sustainment of inflammatory response, the receptor for advanced glycation end products (RAGE) has a variety of ligands, such as advanced glycation end products (AGEs), S100/calcium granule protein, and high-mobility group protein 1 (HMGB1). Recently, an increasing number studies have shown that RAGE ligand binding can initiate the intracellular signal cascade, affect intracellular signal transduction, stimulate the release of cytokines, and play a vital role in the occurrence and development of immune-related diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and Alzheimer's disease. In addition, other RAGE signaling pathways can play crucial roles in life activities, such as inflammation, apoptosis, autophagy, and endoplasmic reticulum stress. Therefore, the strategy of targeted intervention in the RAGE signaling pathway may have significant therapeutic potential, attracting increasing attention. In this paper, through the systematic induction and analysis of RAGE-related signaling pathways and their regulatory mechanisms in immune-related diseases, we provide theoretical clues for the follow-up targeted intervention of RAGE-mediated diseases.
Insights
The receptor for advanced glycation end products (RAGE) pathway is crucial in immune diseases. Targeting RAGE offers potential therapeutic strategies for conditions like lupus and Alzheimer's disease.
Area of Science:
- Immunology
- Molecular Biology
- Biochemistry
Background:
- The receptor for advanced glycation end products (RAGE) is a key mediator in inflammatory responses.
- RAGE ligands include advanced glycation end products (AGEs), S100 proteins, and high-mobility group protein 1 (HMGB1).
- RAGE signaling is implicated in various immune-related diseases such as systemic lupus erythematosus, rheumatoid arthritis, and Alzheimer's disease.
Purpose of the Study:
- To systematically analyze RAGE-related signaling pathways and their regulatory mechanisms in immune-related diseases.
- To explore the therapeutic potential of targeting RAGE signaling pathways.
Main Methods:
- Review and synthesis of existing literature on RAGE signaling.
- Analysis of RAGE's role in the pathogenesis of immune-related diseases.
- Examination of RAGE's involvement in cellular processes like inflammation, apoptosis, autophagy, and endoplasmic reticulum stress.
Main Results:
- RAGE activation initiates intracellular cascades, affecting signal transduction and cytokine release.
- RAGE signaling pathways are integral to the development and progression of multiple immune-related diseases.
- Intervention in RAGE pathways demonstrates significant therapeutic promise.
Conclusions:
- Targeting RAGE signaling pathways presents a viable therapeutic strategy for RAGE-mediated diseases.
- Understanding RAGE's regulatory mechanisms provides theoretical basis for future drug development.
- Further research into RAGE pathways can lead to novel treatments for inflammatory and immune disorders.
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Proteoglycans
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Adherens Junctions
Adherens Junctions are Dynamic

